<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>COVID-19: Diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">COVID-19: Diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">COVID-19: Diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Angela M Caliendo, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kimberly E Hanson, MD, MHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4011005473"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>At the end of 2019, a novel coronavirus now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in the Hubei Province of China. It rapidly spread, resulting in a global pandemic. In February 2020, the World Health Organization (WHO) named the disease COVID-19, which stands for coronavirus disease 2019 [<a href="#rid1">1</a>]. </p><p>Guidance has been issued by public health and other expert organizations throughout the world, including the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Femergencies%2Fdiseases%2Fnovel-coronavirus-2019%2Ftechnical-guidance&amp;token=6mXYIWRNeGuRBDztc0ikcx%2FscIH17x5CKTjm%2FQ5raI%2BhwCh5c71WqQ9R9tsNhJx%2BEpnuKumThFrcmSBNouVEawrja%2FasPUViVSynQSbKTCw%3D&amp;TOPIC_ID=128404" target="_blank">WHO</a> and the United States <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-nCoV%2Fhcp%2Findex.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLETVYV9fJcW0p5%2FSZ3txP%2BHM5kLLHknys0%2FgSZyXivAUDtgQTTNyLN5lgxmxNs%2B4jK8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=128404" target="_blank">Centers for Disease Control and Prevention (CDC)</a> [<a href="#rid2">2,3</a>]. Links to these and other related society guidelines are found elsewhere. (See <a class="local">'Society guideline links'</a> below.)</p><p>This topic will discuss the diagnosis of COVID-19. The clinical features, epidemiology, virology, and prevention of COVID-19 are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/128323.html" rel="external">"COVID-19: Clinical features"</a> and  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention"</a>.)</p><p>The management of COVID-19 is also discussed in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127759.html" rel="external">"COVID-19: Evaluation of adults with acute illness in the outpatient setting"</a> and  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection"</a>.)</p><p></p><p>In addition, please refer to our <a class="external" href="/landing/covid19" target="_blank">COVID-19 homepage</a> to view the complete list of UpToDate COVID-19 topics.</p><p class="headingAnchor" id="H1282456413"><span class="h1">DIAGNOSTIC APPROACH</span></p><p class="headingAnchor" id="H971335344"><span class="h2">Clinical suspicion</span><span class="headingEndMark"> — </span>The possibility of COVID-19 should be considered in anyone with new-onset fever and/or respiratory symptoms. Although cough and dyspnea are considered the classic respiratory features of COVID-19, other respiratory symptoms such as sore throat, rhinorrhea, and nasal congestion are commonly reported and are frequently the sole presenting symptoms of COVID-19. Other common clinical manifestations include smell or taste disturbances, myalgias, and diarrhea  (<a class="graphic graphic_table graphicRef127890" href="/z/d/graphic/127890.html" rel="external">table 1</a>). COVID-19 should also be considered in patients with severe lower respiratory tract illness without another clear cause. (See  <a class="medical medical_review" href="/z/d/html/128323.html" rel="external">"COVID-19: Clinical features", section on 'Initial presentation'</a>.)</p><p>As SARS-CoV-2 is prevalent worldwide, clinicians should have a low threshold for suspicion of COVID-19. The threshold for suspicion should be particularly low if the individual resides in or has traveled to locations with high rates of community transmission, has had potential exposure to SARS-CoV-2 in an outbreak setting or as a close contact of someone with confirmed or suspected infection, or resides in a congregate setting. </p><p>There are no specific clinical features that can reliably distinguish COVID-19 from other viral respiratory infections [<a href="#rid4">4</a>]. Nevertheless, some features may warrant a higher level of clinical suspicion [<a href="#rid5">5-7</a>]. Several studies have suggested that loss of taste and loss of smell are the symptoms most strongly associated with a positive SARS-CoV-2 test [<a href="#rid6">6,8,9</a>]. Development of dyspnea several days after the onset of initial symptoms is also suggestive of COVID-19 [<a href="#rid5">5</a>]. However, none of these findings definitively establish the diagnosis of COVID-19 without microbiologic testing. </p><p>COVID-19 should also be a diagnostic consideration in patients who present with extrapulmonary complications that have been associated with SARS-CoV-2 infection, including cardiac injury, ischemic stroke and other thromboembolic events, and inflammatory complications (eg, the multisystem inflammatory syndrome in children). (See  <a class="medical medical_review" href="/z/d/html/128323.html" rel="external">"COVID-19: Clinical features", section on 'Acute course and complications'</a>.) </p><p>Patients with suspected COVID-19 who do not need emergency care should be encouraged to call prior to presenting to a health care facility for evaluation. Many patients can be evaluated regarding the need for testing over the phone. For patients in a health care facility, infection control measures should be implemented as soon as the possibility of COVID-19 is suspected. (See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Infection prevention in the health care setting'</a>.) </p><p class="headingAnchor" id="H1671759840"><span class="h2">Whom to test</span></p><p class="headingAnchor" id="H2963521245"><span class="h3">Symptomatic patients</span><span class="headingEndMark"> — </span>If possible, all symptomatic patients with suspected infection (see <a class="local">'Clinical suspicion'</a> above) should undergo testing; the diagnosis cannot be definitively made without microbiologic testing. </p><p>However, in some resource-limited settings, limited capacity may preclude testing all patients with suspected COVID-19. Local health departments may have specific criteria for testing. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.idsociety.org%2Fglobalassets%2Fidsa%2Fpublic-health%2Fcovid-19-prioritization-of-dx-testing.pdf&amp;token=7nXx239aZu5qGiD0D9Tun4YWD5D3HYDQDWZN2PEbSrvao%2FOu9RQ1xU0wXOmK%2BgGpLvO01YUyqPWVmM1QkvSE8i9bKtVnZX0Ts1dSn%2BV9rDzSA42fCPo2DXXxFfnJhOna&amp;TOPIC_ID=128404" target="_blank">Infectious Diseases Society of America (IDSA)</a> has suggested priorities for testing when testing capacity is limited  (<a class="graphic graphic_table graphicRef127515" href="/z/d/graphic/127515.html" rel="external">table 2</a>); high-priority individuals include hospitalized patients (especially critically ill patients with unexplained respiratory illness) and symptomatic individuals who are health care workers or first responders, work or reside in congregate living settings, or have risk factors for severe disease [<a href="#rid10">10</a>]. </p><p>The European Centre for Disease Prevention and Control has also suggested <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ecdc.europa.eu%2Fen%2Fcovid-19%2Fsurveillance%2Ftesting-strategies&amp;token=dGr9cEMlIkRgn86LzPlEn6EQQv5sveueIO3QrAxQTHm0YxxRsEqiYXgN9R2egonxAoRUi74tmhTth9N5wR0fmfJ7QYg3RlKGgdLdOoHZsrE%3D&amp;TOPIC_ID=128404" target="_blank">testing strategies</a> when testing resources are limited. </p><p>Testing criteria suggested by the World Health Organization (WHO) can be found in its <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Femergencies%2Fdiseases%2Fnovel-coronavirus-2019%2Ftechnical-guidance-publications&amp;token=QuVnayyJyqad70EFsJj6nsDYLl2bLkGTraPvkLvWEu%2Bixu%2Fc4hcEq%2Fck%2FD1%2FWE8WnU2qPbKmQURSJbxsA3F5cwWKgKUMxCpzkRjDA32PpQwI0CjSMGMeqvBKovJBxLNT&amp;TOPIC_ID=128404" target="_blank">technical guidance online</a>. </p><p class="headingAnchor" id="H2321618902"><span class="h3">Selected asymptomatic individuals</span><span class="headingEndMark"> — </span>Testing certain asymptomatic individuals may also be important for public health or infection control purposes, particularly when community transmission rates are high. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>The primary reason to test an asymptomatic individual:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Following close contact with an individual with COVID-19 (this includes neonates born to mothers with COVID-19). The time to detectable ribonucleic acid (RNA) following exposure is unknown, so the optimal time to test for COVID-19 following exposure is uncertain. The Centers for Disease Control and Prevention (CDC) recommends testing once five days have passed since the last exposure [<a href="#rid11">11</a>]; we typically test five to seven days post-exposure. This and other post-exposure precautions are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Post-exposure management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other potential reasons for screening for SARS-CoV-2 infection include:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Early identification of infection in congregate living facilities that house individuals at risk for severe disease (eg, long-term care facilities, correctional and detention facilities, homeless shelters). This includes testing in response to identified COVID-19 cases within the facility as well as intermittent screening of employees and residents. (See  <a class="medical medical_review" href="/z/d/html/128349.html" rel="external">"COVID-19: Management in nursing homes", section on 'Preventing infection'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Screening hospitalized patients, prior to surgical or aerosol-generating procedures, particularly at locations where prevalence is high (eg, ≥10 percent polymerase chain reaction [PCR] positivity in the community).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prior to receiving immunosuppressive therapy (including prior to transplantation) [<a href="#rid12">12,13</a>]. (See  <a class="medical medical_review" href="/z/d/html/127582.html" rel="external">"COVID-19: Issues related to solid organ transplantation", section on 'Pretransplantation screening'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to avoid testing in asymptomatic individuals</strong> – In the United States, the CDC suggests not testing for new infection in asymptomatic individuals who were previously diagnosed with SARS-CoV-2 within the prior month. A nucleic acid amplification test (NAAT), specifically, should be avoided in individuals who have had SARS-CoV-2 infection within the prior three months because of the low likelihood that a repeat positive NAAT during this interval represents an active reinfection. (See <a class="local">'Persistent or recurrent positive NAAT during convalescence'</a> below.)</p><p></p><p>Testing individuals with a known diagnosis of SARS-CoV-2 infection to determine the duration of isolation and precautions is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Discontinuation of precautions'</a>.)</p><p class="headingAnchor" id="H4291362019"><span class="h2">Choosing an initial diagnostic test</span><span class="headingEndMark"> — </span>A viral test is necessary to make the diagnosis of SARS-CoV-2 infection: either an NAAT, most commonly a reverse-transcription polymerase chain reaction (RT-PCR) assay, or an antigen test  (<a class="graphic graphic_table graphicRef128419" href="/z/d/graphic/128419.html" rel="external">table 3</a>). </p><p>In general, we suggest NAAT, if readily available with reasonable turnaround time (eg, within 24 to 48 hours), because of its superior sensitivity. NAATs are usually performed at a laboratory. Rapid RT-PCR tests that can be performed at the point-of-care are also available and appear to perform comparably to standard laboratory-based NAAT; rapid isothermal tests may be less sensitive than other rapid NAAT [<a href="#rid12">12</a>]. (See <a class="local">'NAAT (including RT-PCR)'</a> below.)</p><p>However, antigen tests are more accessible, more convenient, and less costly than NAAT and have a shorter turnaround time than laboratory-based NAAT. Thus, they are reasonably used more commonly than NAAT for testing at home and at point-of-care sites. Individuals who use antigen testing should be aware that the sensitivity is lower than that of NAATs and negative antigen tests performed for symptoms or recent exposure generally warrant confirmation with additional testing  (<a class="graphic graphic_algorithm graphicRef134206" href="/z/d/graphic/134206.html" rel="external">algorithm 1</a>). (See <a class="local">'Antigen testing'</a> below.) </p><p>Antigen tests are also preferable to NAAT for individuals who had recently (ie, in the prior three months) tested positive for SARS-CoV-2 and have indications for repeat testing (eg, new symptoms); in the few months following infection, a positive NAAT may be more likely to reflect prolonged viral RNA shedding than a new infection, but it cannot distinguish between the two. (See <a class="local">'Persistent or recurrent positive NAAT during convalescence'</a> below.)</p><p class="headingAnchor" id="H4048697218"><span class="h2">Specimen collection</span><span class="headingEndMark"> — </span>Upper respiratory samples are the primary specimens for SARS-CoV-2 viral tests.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specimens for NAAT</strong> – In the United States, the CDC recommends collection of one of the following specimens [<a href="#rid14">14</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nasopharyngeal swab specimen, collected by a health care professional </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nasal swab specimen from both anterior nares, collected by a health care professional or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Ftesting%2FHow-To-Collect-Anterior-Nasal-Specimen-for-COVID-19.pdf&amp;token=IvIam9aHdqLZYQFRYgWJbkxr35Q3ZfDJTN9fZIyThX8wodijj%2F1HHPK6og5aMVKubpJnJpCd0BDLm70OKeDt51nt3ajIducYLmeGTyHw2t%2BobRb1GXDCxw0IHWfU4hZEf3UzwlAjeryZnCedRqt8Gg%3D%3D&amp;TOPIC_ID=128404" target="_blank">by the patient</a> on-site or at home (using a flocked or spun polyester swab)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nasal mid-turbinate swab, collected by a health care professional or by the patient supervised on-site (using a flocked taper swab)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nasal or nasopharyngeal wash/aspirate, collected by a health care professional</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oropharyngeal swab specimen, collected by a health care professional </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Saliva specimen (1 to 5 mL) collected by the patient while supervised</p><p></p><p class="bulletIndent1">There is uncertainty regarding the optimal upper respiratory tract specimen for NAAT. The IDSA suggests a nasopharyngeal swab, a mid-turbinate swab, an anterior nasal swab, saliva, or a combined anterior nasal/oropharyngeal swab rather than an oropharyngeal swab because of limited data suggesting lower sensitivity with oropharyngeal specimens [<a href="#rid12">12</a>]. Test sensitivity with different specimens is discussed elsewhere. (See <a class="local">'Accuracy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specimens for antigen tests</strong> – Nasopharyngeal, nasal mid-turbinate, and nasal swabs are the only recommended specimens. Antigen tests are not validated for use with oral or salivary specimens. </p><p></p><p>Patients who collect their own specimens (of any type) should be given detailed instructions on correct technique. </p><p>Additional information on <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-nCoV%2Flab%2Fguidelines-clinical-specimens.html&amp;token=cP7AZAOzbyhT0z1XODeZq2%2B56hhHfWCRCrsc%2B%2BMvNbdZEaSH2ITSt3kQzYw0suIrRC3zzh2JeipnU%2BS%2BEnsjinkZ0p4sqTXsqHo9FO%2BVqmrER3Iu%2FohnyTCaRuaBMAqC&amp;TOPIC_ID=128404" target="_blank">testing and handling</a> of clinical specimens can be found at the CDC website. </p><p>Infection control practices during specimen collection are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Specimen collection for respiratory viral pathogens'</a>.)</p><p>Although SARS-CoV-2 RNA can be detected in nonrespiratory specimens (eg, stool, ocular specimens, blood), testing of these specimens has a limited role in the diagnosis of COVID-19 [<a href="#rid15">15-17</a>].</p><p class="headingAnchor" id="H1836493568"><span class="h2">Diagnosis of SARS-CoV-2 infection</span><span class="headingEndMark"> — </span>The diagnosis of COVID-19 is made by direct detection of SARS-CoV-2 RNA using NAATs or by detection of viral protein using an antigen test. A positive NAAT or antigen test is generally indicative of infection and does not need to be repeated. </p><p>Interpretation and further evaluation following a negative test vary for NAAT versus antigen testing and are discussed elsewhere. (See <a class="local">'NAAT interpretation'</a> below and <a class="local">'Antigen test interpretation'</a> below.)</p><p class="headingAnchor" id="H3556263225"><span class="h2">Identifying specific variants</span><span class="headingEndMark"> — </span>In general, clinically available diagnostic tests cannot confirm the specific SARS-CoV-2 variant causing infection. Viral sequencing or dedicated multiplex PCR genotype testing is needed to do this, and these methods are not routinely available for clinical decision-making. </p><p>Certain variants result in an S gene target failure with some NAATs (ie, the S gene is not detected but the NAAT results are positive because the other target is detected). Such results can be a proxy for infection with those particular variants if other circulating variants do not result in S gene target failure. However, this is not a definitive method of variant identification. Because different NAATs detect different regions of the S gene, a particular viral variant may result in S gene target failure with one NAAT but not another. Furthermore, laboratories do not routinely provide information on S gene target failure. (See <a class="local">'Impact of SARS-CoV-2 mutations/variants on test accuracy'</a> below.)</p><p class="headingAnchor" id="H1110013073"><span class="h2">Testing for other pathogens</span><span class="headingEndMark"> — </span>If influenza and respiratory syncytial virus (RSV) are circulating in the community, it is reasonable to also test for these viruses when testing for SARS-CoV-2, as this could have management implications. Depending on the presentation (eg, symptoms consistent with pneumonia, pharyngitis), testing for other pathogens may also be warranted. These are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/117561.html" rel="external">"Overview of community-acquired pneumonia in adults", section on 'Microbiologic testing'</a> and  <a class="medical medical_review" href="/z/d/html/6867.html" rel="external">"Evaluation of acute pharyngitis in adults", section on 'Evaluation'</a>.)</p><p>However, detection of another viral (or bacterial) pathogen does not necessarily rule out SARS-CoV-2 in locations where there is widespread transmission. Coinfection with SARS-CoV-2 and other respiratory pathogens, including influenza virus, has been described, but the reported frequency is variable [<a href="#rid18">18-22</a>].</p><p class="headingAnchor" id="H2358377675"><span class="h1">NAAT (INCLUDING RT-PCR)</span></p><p class="headingAnchor" id="H3233487926"><span class="h2">Types of NAATs</span><span class="headingEndMark"> — </span>Nucleic acid amplification tests (NAATs) detect SARS-CoV-2 RNA; reverse-transcription polymerase chain reaction (RT-PCR) assays are the most common type of NAAT  (<a class="graphic graphic_table graphicRef128419" href="/z/d/graphic/128419.html" rel="external">table 3</a>) [<a href="#rid23">23,24</a>]. Various RT-PCR assays are used around the world; different assays amplify and detect different regions of the SARS-CoV-2 genome. Some target two or more genes, including the nucleocapsid (N), envelope (E), and spike (S) genes, and regions in the first open reading frame, including the RNA-dependent RNA polymerase (RdRp) gene [<a href="#rid25">25</a>]. Other, less common types of NAAT include isothermal amplification, CRISPR-based assays, and next-generation sequencing [<a href="#rid26">26-28</a>]. </p><p>In the United States, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedical-devices%2Femergency-situations-medical-devices%2Femergency-use-authorizations-medical-devices&amp;token=nM7H6bApqRRftmLKRhh9u0U5uGKZ2RuexWl2Xyh5mMwceXImtYk3RzgFab6db%2Ba035MxqYmbgzlLTnC5YfScGSaNP7una6Uw4iZbtmQ5RSU%3D&amp;TOPIC_ID=128404" target="_blank">Food and Drug Administration (FDA) has granted emergency use authorization (EUA)</a> for many different NAAT assays [<a href="#rid29">29</a>]; testing is performed by the Centers for Disease Control and Prevention (CDC), local public health departments, hospital laboratories, and commercial laboratories. For some assays, the patient can collect the specimen at home and submit it to a laboratory [<a href="#rid30">30,31</a>]; point-of-care NAATs, some of which can be completed at home, have also been developed, although they may be less sensitive than laboratory-based tests [<a href="#rid26">26,32-35</a>]. </p><p>Specific NAAT assays have different performance characteristics and times to results (ranging from 15 minutes to several hours) and are authorized for different specimen types. For laboratory-performed tests, the turnaround time for clinicians to receive a result also depends on how often the laboratory performs the test. </p><p>Pooled specimen testing with NAATs (ie, testing several specimens together and only retesting individual specimens if the pool tests positive) can improve laboratory testing capacity [<a href="#rid36">36-39</a>]. However, this approach would not save time and resources in high-prevalence settings, since frequent retesting for pools that test positive is cumbersome; thus, it is best reserved for populations with expected low prevalence, such as asymptomatic individuals without known exposure. Clinicians should be aware that pooling specimens reduces test sensitivity (to greater extents with larger pool sizes) and may prolong the time to an individual positive result. </p><p class="headingAnchor" id="H2048721763"><span class="h2">NAAT interpretation</span></p><p class="headingAnchor" id="H2933382153"><span class="h3">Positive NAAT result</span><span class="headingEndMark"> — </span>A positive nucleic acid amplification test (NAAT; eg, RT-PCR) for SARS-CoV-2 generally confirms the diagnosis of COVID-19. No additional diagnostic testing is necessary. However, additional testing may be warranted for management in hospitalized patients. This is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Evaluation'</a>.)</p><p>Patients with COVID-19 can have detectable SARS-CoV-2 RNA in upper respiratory tract specimens for weeks after the onset of symptoms [<a href="#rid40">40</a>]; however, prolonged viral RNA detection does not necessarily indicate ongoing infectiousness [<a href="#rid41">41,42</a>]. These data and the implications for discontinuing isolation precautions are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Viral shedding and period of infectiousness'</a> and  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Discontinuation of precautions'</a>.) </p><p>There have also been reports of patients with COVID-19 who have positive NAATs soon after documented viral RNA clearance. Thus far, there is no evidence that this finding represents relapsed or repeat infection [<a href="#rid43">43</a>]. </p><p class="headingAnchor" id="H242842153"><span class="h3">Negative initial NAAT result</span><span class="headingEndMark"> — </span>For many individuals, a single negative NAAT result is sufficient to exclude the diagnosis of COVID-19. However, false-negative NAATs (eg, RT-PCR) from upper respiratory specimens have been well documented (see <a class="local">'Accuracy'</a> below). If initial testing is negative but the suspicion for COVID-19 remains (eg, suggestive symptoms without evident alternative cause) and confirming the presence of infection is important for management or infection control, we suggest repeating the test. The optimal timing for repeat testing is not known; it is generally performed 24 to 48 hours after the initial test. Repeat testing within 24 hours is not recommended. </p><p>In patients with evidence of lower respiratory tract illness, lower respiratory tract specimens can be an option for NAAT [<a href="#rid12">12,44</a>]. We agree with IDSA and WHO recommendations to reserve lower respiratory tract specimen NAATs for hospitalized patients who have an initial negative test on an upper respiratory tract specimen but for whom suspicion for lower respiratory tract SARS-CoV-2 infection remains [<a href="#rid12">12,45</a>]. For lower respiratory tract specimens, expectorated sputum should be collected from patients with productive cough, and tracheal aspirate or bronchoalveolar lavage should be collected from patients who are intubated. Most NAATs have not received EUA for lower respiratory samples, so laboratories need to validate these specimen types, and this may not be possible for all laboratories. Induction of sputum is not recommended. </p><p>In hospitalized patients suspected of having COVID-19 who have a negative SARS-CoV-2 NAAT, characteristic laboratory or imaging findings can further support the clinical diagnosis of COVID-19 and be reasons to maintain infection control precautions (see  <a class="medical medical_review" href="/z/d/html/128323.html" rel="external">"COVID-19: Clinical features", section on 'Laboratory findings'</a> and  <a class="medical medical_review" href="/z/d/html/128323.html" rel="external">"COVID-19: Clinical features", section on 'Imaging findings'</a>). It is also important to consider other potential causes of symptoms in patients with negative SARS-CoV-2 NAATs.</p><p>For patients who present three to four weeks into the course of illness and have negative NAAT, checking a serologic test may be informative [<a href="#rid46">46,47</a>]. If serology is performed in this setting, we suggest an IgG test; a total antibody test is also likely useful, but data are limited for this situation. A reactive IgG would be suggestive of COVID-19, whereas a negative test could suggest a decreased likelihood. However, the reliability of the serologic test result depends on the specific assay and the duration of illness. (See <a class="local">'Serology to identify prior/late infection'</a> below.)</p><p>Infection control precautions for COVID-19 should continue while repeat evaluation is being performed. (See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection"</a>.)</p><p>In many cases, because of the limited availability of testing and concern for false-negative results, the diagnosis of COVID-19 is made presumptively based on a compatible clinical presentation in the setting of an exposure risk (residence in or travel to an area with widespread community transmission or known contact) in the absence of other identifiable causes. </p><p class="headingAnchor" id="H1974868934"><span class="h3">Indeterminate NAAT result</span><span class="headingEndMark"> — </span>The interpretation of an inconclusive or indeterminate result depends on the specific nucleic acid amplification test (NAAT) performed; the clinician should confer with the performing laboratory about additional testing.</p><p>In some cases, an inconclusive or indeterminate result indicates that only one of the two or more genes that the NAAT targets was identified. These results can be considered presumptive positive results, given the high specificity of NAAT assays. If the patient is early in the disease course, repeat testing can be helpful to confirm.</p><p class="headingAnchor" id="H3384281277"><span class="h2">Accuracy</span><span class="headingEndMark"> — </span>The accuracy and predictive values of SARS-CoV-2 NAATs have not been systematically evaluated. They are highly specific tests [<a href="#rid48">48,49</a>]. Although NAATs have high analytic sensitivity in ideal settings (ie, they are able to accurately detect low levels of viral RNA in test samples known to contain viral RNA), clinical performance is more variable  (<a class="graphic graphic_table graphicRef128419" href="/z/d/graphic/128419.html" rel="external">table 3</a>). </p><p>False-positive results are rare but have been reported with certain platforms [<a href="#rid50">50</a>]. </p><p>Reported false-negative rates have ranged from less than 5 to 40 percent, although these estimates are limited, in part because there is no perfect reference standard for comparison [<a href="#rid51">51,52</a>]. As an example, in a study of 51 patients who were hospitalized in China with fever or acute respiratory symptoms and ultimately had a positive SARS-CoV-2 RT-PCR test (mainly on throat swabs), 15 patients (29 percent) had a negative initial test and only were diagnosed by serial testing [<a href="#rid53">53</a>]. In a similar study of 70 patients in Singapore, initial nasopharyngeal testing was negative in 8 patients (11 percent) [<a href="#rid54">54</a>]. In both studies, rare patients were repeatedly negative and only tested positive after four or more tests. However, lower false-negative rates have also been suggested. In one study of 626 patients who had a repeat nasopharyngeal RT-PCR test within seven days of an initial negative test at two large health centers in the United States, 3.5 percent of the repeat tests were positive [<a href="#rid52">52</a>]. </p><p>Sensitivity of testing likely depends on the type and quality of the specimen obtained, the duration of illness at the time of testing, and the specific assay: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Test performance by specimen type</strong> – Test sensitivity may vary by type of specimen. </p><p></p><p class="bulletIndent1">Among upper respiratory tract specimens, nasopharyngeal, nasal, and saliva specimens have high sensitivity, whereas the sensitivity of oropharyngeal swab specimens is lower [<a href="#rid12">12,55-58</a>]. In a meta-analysis of 23 studies that included approximately 8000 participants, compared with PCR results on nasopharyngeal swab specimens, the pooled sensitivities were 86 percent for nasal swabs, 85 percent for saliva samples, and 68 percent for throat swabs [<a href="#rid58">58</a>]. The combination of nasal and throat swabs was 97 percent. However, there was substantial heterogeneity across studies (eg, in timing of testing, inclusion of asymptomatic patients, and method of collection for saliva specimens), and some of them were unpublished. Furthermore, only two studies contributed data on throat swabs, and these had relatively different findings (50 versus 82 percent sensitivity) [<a href="#rid41">41,56</a>]. Self-collected specimens can reduce the need for personal protective equipment since a health care provider is not directly collecting the specimens. Accuracy of NAAT appears to be relatively good when nasal swabs and saliva specimens are self-collected. The sensitivity of NAAT with self-collected nasal or nasal mid-turbinate specimens appears similar to that with nasopharyngeal specimens collected by a health care provider [<a href="#rid59">59,60</a>]. </p><p></p><p class="bulletIndent1">Lower respiratory tract specimens may have higher viral loads and be more likely to yield positive tests than upper respiratory tract specimens [<a href="#rid55">55,61</a>]. In a study of 205 patients with COVID-19 who were sampled at various sites, the highest rates of positive viral RNA tests were reported from bronchoalveolar lavage (95 percent, 14 of 15 specimens) and sputum (72 percent, 72 of 104 specimens), compared with oropharyngeal swab (32 percent, 126 of 398 specimens) [<a href="#rid55">55</a>]. </p><p></p><p class="bulletIndent1">The variable performance of NAAT by specimen type may depend on the viral variant, although further studies are needed. Limited evidence from small studies suggests that saliva may be more sensitive than nasal specimens for the Omicron variant [<a href="#rid62">62,63</a>]. (See <a class="local">'Impact of SARS-CoV-2 mutations/variants on test accuracy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Test performance by illness duration</strong> – The likelihood of detectable SARS-CoV-2 RNA may also vary by the duration of illness [<a href="#rid64">64,65</a>]. In an analysis of seven studies (including two unpublished reports) that evaluated RT-PCR performance by time since symptom onset or exposure, the estimated rates of false-negative results were 100 percent on the day of exposure, 38 percent on day 5 (estimated as the first day of symptoms), 20 percent at day 8, and 66 percent at day 21 [<a href="#rid64">64</a>]. Heterogeneity across studies and assumptions made in the analysis (eg, about incubation period and time of exposure) reduce confidence in these results. One of the studies included in the analysis used a combination of RT-PCR and an immunoglobulin M (IgM) serologic test to make the diagnosis of COVID-19 and suggested that RT-PCR negative rates were &lt;10 percent on days 1 to 3 of illness, &gt;20 percent at day 6, and &gt;50 percent after day 14; however, these results should also be interpreted with caution, since the serologic test used was not validated for detection of acute infection and IgM tests are frequently falsely positive [<a href="#rid65">65</a>]. Other studies have also suggested that viral RNA levels are high prior to the development of symptoms (ie, in presymptomatic patients) [<a href="#rid66">66</a>]. Nevertheless, low viral RNA levels should not be interpreted as reflecting a late stage of infection, as they may be low at the outset as well [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Viral shedding and period of infectiousness'</a>.)</p><p></p><p class="bulletIndent1">Data on test performance and viral RNA levels in asymptomatic patients are limited [<a href="#rid66">66</a>]. It is unknown how soon viral RNA can be detectable following exposure and infection. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Test performance by assay type</strong> – There are differences in the limit of detection among the major commercial NAAT assays, and retesting samples on different platforms may yield conflicting results [<a href="#rid48">48,49</a>]. Additionally, certain point-of-care or rapid NAAT assays may not be as sensitive as standard laboratory-based tests [<a href="#rid12">12,33,35,68</a>]. In a systematic review conducted by the IDSA, rapid RT-PCR tests had similar sensitivity as standard laboratory-based NAAT (98 percent for both) when compared with a composite reference standard (ie, the combined results of multiple tests), whereas the sensitivity of the Abbott ID NOW test (a rapid isothermal test), was lower than laboratory-based NAAT (81 versus 99 percent) [<a href="#rid12">12</a>]. All methods had specificity ≥97 percent. </p><p></p><p class="headingAnchor" id="H3683993212"><span class="h2">Cycle threshold</span><span class="headingEndMark"> — </span>The cycle threshold (Ct) refers to the number of cycles in an RT-PCR assay needed to amplify viral RNA to reach a detectable level. The Ct value can thus indicate the relative viral RNA level in a specimen (with lower Ct values reflective of higher viral levels). Resulting laboratories generally do not provide the Ct value with the qualitative NAAT result, although it can be obtained upon request for some testing platforms. However, the clinical application of the Ct is uncertain [<a href="#rid69">69</a>]. Ct values are not standardized across RT-PCR platforms, so results cannot be compared across different tests. Furthermore, no clinical studies have validated use of Ct to guide management. </p><p class="headingAnchor" id="H2498598133"><span class="h1">ANTIGEN TESTING</span><span class="headingEndMark"> — </span>Tests that detect SARS-CoV-2 antigen can be performed rapidly and at the point of care and thus are more accessible with a faster time to results than most nucleic acid amplification tests (NAATs); various home antigen tests, performed on nasal swabs, allow individuals to test themselves without presenting to medical care or a testing site. Antigen tests are typically less sensitive than NAATs  (<a class="graphic graphic_table graphicRef128419" href="/z/d/graphic/128419.html" rel="external">table 3</a>) [<a href="#rid35">35,70,71</a>]. Nevertheless, they can be useful when NAATs are inconvenient or unavailable or when NAAT turnaround times are too long to be clinically useful, provided that clinicians (and individuals who self-test) are aware of the possibility of false negatives and the results are interpreted based on the pretest probability of COVID-19. </p><p class="headingAnchor" id="H3025653108"><span class="h2">Antigen test interpretation</span></p><p class="headingAnchor" id="H2480327173"><span class="h3">In symptomatic patients</span><span class="headingEndMark"> — </span>Antigen tests can be useful alternatives to NAAT for diagnosis of SARS-CoV-2 in symptomatic individuals [<a href="#rid72">72,73</a>]. In such cases, the test should be performed within the first five to seven days of symptoms. Although antigen testing cannot detect virus at levels as low as NAAT can, its sensitivity is greatest in the first week of symptoms, when virus replication is at its highest. </p><p class="bulletIndent1"><span class="glyph">●</span>A positive antigen test in a symptomatic individual is indicative of SARS-CoV-2 infection  (<a class="graphic graphic_algorithm graphicRef134206" href="/z/d/graphic/134206.html" rel="external">algorithm 1</a>). The false-positive rate is very low. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A negative antigen test in a symptomatic individual could represent a false negative, does not exclude the possibility of SARS-CoV-2 infection, and should be followed by additional testing. Individuals testing at home should repeat an antigen test at 48 hours; this is consistent with recommendations from the US Food and Drug Administration (FDA) [<a href="#rid74">74</a>]. For individuals who are willing to repeat testing with an NAAT (rather than antigen testing), we suggest this approach given the greater sensitivity of NAAT. If the repeat test (with either an antigen test or NAAT) is negative, the likelihood of COVID-19 is low, but testing can be repeated if concern for COVID-19 remains following two negative antigen tests. </p><p></p><p class="bulletIndent1">Although the sensitivity of antigen testing is higher in symptomatic than in asymptomatic individuals, it remains lower than that of NAAT. Sensitivity is improved with repeating antigen testing. (See <a class="local">'Accuracy'</a> below.)</p><p></p><p class="headingAnchor" id="H643165170"><span class="h3">For post-exposure testing</span><span class="headingEndMark"> — </span>Antigen tests can be useful to evaluate for SARS-CoV-2 following close contact with an individual with known or suspected SARS-CoV-2 infection. In order to identify new infections, the CDC recommends that individuals get tested once five days have passed since the last exposure [<a href="#rid11">11</a>]; we typically test five to seven days post-exposure.</p><p class="bulletIndent1"><span class="glyph">●</span>A positive antigen test in an asymptomatic individual following exposure is generally indicative of SARS-CoV-2 infection  (<a class="graphic graphic_algorithm graphicRef134206" href="/z/d/graphic/134206.html" rel="external">algorithm 1</a>). The false-positive rate is very low.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A negative antigen test in an asymptomatic individual following exposure could represent a false negative and should generally be followed by additional testing. The FDA recommends that individuals testing at home repeat antigen testing two additional times, each 48 hours apart (for a total of three tests) [<a href="#rid74">74</a>]. It is also reasonable to confirm an initial negative antigen test with a follow-up NAAT instead. If all the repeat testing is negative, the likelihood of COVID-19 is low. Any positive test performed in this setting is indicative of infection. </p><p></p><p class="bulletIndent1">The decision to repeat a negative antigen test should take into account the potential transmission impact of an individual with a false-negative test, which depends on other factors, including vaccination rates in the community, use of masks, and extent of exposure. Repeat testing may reasonably be deferred if the potential impact of a false-negative antigen test is low. Regardless of whether a negative test is confirmed, individuals with known exposure should self-monitor for symptoms of COVID-19 after exposure and get tested if they develop.</p><p></p><p class="bulletIndent1">Among asymptomatic individuals, the sensitivity of antigen testing is lower than that among symptomatic individuals, and the predictive value of a negative antigen test may be limited [<a href="#rid73">73</a>]. Sensitivity is improved with repeating antigen testing, and three serial tests are more sensitive than two among asymptomatic individuals [<a href="#rid75">75</a>]. (See <a class="local">'Accuracy'</a> below.)</p><p></p><p class="headingAnchor" id="H1383591999"><span class="h3">For other screening purposes</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serial screening in congregate settings</strong> – Antigen tests may be useful in outbreak settings and for repeated screening of individuals in high-risk congregate settings to quickly identify individuals with SARS-CoV-2 and isolate them; modelling studies have suggested that if the frequency of testing is high enough, even antigen tests with lower sensitivity could be successfully used to reduce cumulative infection rates [<a href="#rid76">76</a>]. If used for serial testing in these settings, positive tests indicate infection and negative antigen tests do not need to be confirmed [<a href="#rid77">77</a>]. Studies evaluating transmission outcomes after serial testing are limited, and the optimal frequency and duration of serial antigen testing to sufficiently identify infections have not been established. (See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Screening in selected high-risk settings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testing prior to events</strong> <strong>or gatherings</strong> – Rapid antigen testing prior to events (and only allowing individuals who test negative to enter) has been proposed as a strategy to reduce the risk of outbreaks; in this context, the result of a single antigen test is taken at face value. This approach was evaluated in a randomized trial in Spain, in which 1000 adults were invited to an indoor musical event, tested with antigen and molecular assays, and if negative on antigen test, randomly assigned to enter the venue or go home [<a href="#rid78">78</a>]. Although there were no subsequent cases by day 8 among attendees compared with two among the control group, the impact of antigen testing alone is uncertain since the event was well ventilated and all attendees wore N95 masks. </p><p></p><p class="bulletIndent1">Although data are limited and the efficacy of this approach is uncertain, particularly with the Omicron variant, performing the antigen test within hours of the event (rather than the day before) seems likely to optimize the utility of such testing. There have been reports of outbreaks associated with events at which attendants had negative antigen tests or NAAT on the day of or day prior to the event [<a href="#rid79">79,80</a>].</p><p></p><p>If antigen tests are used in situations when the likelihood of SARS-CoV-2 is low (eg, testing of an asymptomatic individual who has had no household contact with a patient with COVID-19 and lives in a community with low infection rates), a negative antigen test can be interpreted at face value. </p><p>Positive antigen tests generally do not warrant confirmation, even in settings of low prevalence. However, it is reasonable to confirm a positive antigen test with an NAAT when the diagnosis is suspect and prevalence is very low (eg, &lt;1 percent); in that case, a negative NAAT would indicate no infection. </p><p class="headingAnchor" id="H3983709138"><span class="h3">To inform duration of precautions after infection</span><span class="headingEndMark"> — </span>Use of antigen testing in individuals with known infection to inform the duration of isolation and precautions is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Discontinuation of precautions'</a>.)</p><p class="headingAnchor" id="H1507316420"><span class="h2">Accuracy</span><span class="headingEndMark"> — </span>Systematic reviews of studies evaluating antigen test performance indicate that antigen tests have very high specificity but are generally less sensitive than NAAT; they are most sensitive in symptomatic individuals during the first week of illness [<a href="#rid73">73,81,82</a>]. As an example, in a July 2022 systematic review of 152 studies, in which 49 commercially available antigen tests were evaluated on specimens with known SARS-CoV-2 NAAT results, sensitivity was highly variable, while overall specificity exceeded 99 percent [<a href="#rid82">82</a>]. Average sensitivity was higher among symptomatic compared with asymptomatic participants (73 versus 55 percent) and was higher during the first compared with second week after symptom onset (81 versus 54 percent). Other studies have suggested that antigen test specificity peaks approximately four days after symptom onset [<a href="#rid83">83</a>], although there are many variables that may affect this timing, including the viral variant. </p><p>Serial antigen testing appears to improve sensitivity. In an unpublished prospective study of over 5500 individuals who underwent serial antigen and NAAT testing every 48 hours for two weeks, antigen test sensitivity on the first day of NAAT positivity was 60 percent for symptomatic individuals and 12 percent for asymptomatic individuals [<a href="#rid75">75</a>]. Sensitivity with two or three serial tests increased to 92 and 94 percent for symptomatic individuals and to 51 and 75 percent for asymptomatic individuals. </p><p>Antigen test sensitivity also improves with increasing levels of viral RNA in upper respiratory specimens (ie, as reflected by lower Ct values on NAAT). In the systematic review detailed above, average sensitivity was 94 to 97 percent for Ct value ≤25, 69 percent for Ct value 25 to 30, and 19 percent for Ct value &gt;30 [<a href="#rid82">82</a>].</p><p>Studies have also suggested that a positive antigen test is more likely than a positive RT-PCR test to indicate that infectious virus could be cultured from specimens [<a href="#rid84">84-86</a>]. As an example, in a study of 60 individuals with SARS-CoV-2 infection who underwent daily antigen and viral culture testing, antigen test was positive on 93 percent of specimens that were culture positive but only 28 percent of specimens that were culture negative [<a href="#rid86">86</a>]. However, since infectious virus can still be isolated from antigen-negative specimens, clinicians and patients should be aware that a negative antigen test cannot be used to indicate that a person is not infectious. In other studies, the rate of positive viral culture in specimens that were antigen negative ranged from 9 to 16 percent [<a href="#rid71">71,83</a>]. </p><p>Performance also varies by the specific antigen test. Antigen tests that have been granted EUA in the United States can be found on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedical-devices%2Fcoronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices%2Fin-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2&amp;token=nD4%2Bf0lK%2BEvfURXTxto2hZWteRHna8HSlL3DauGeyLWFXSVvnXFg%2BohuMf9wmd8qzN4gedUDjl4cnwMY6xDc%2FQuCY9kS1D7Ve9FbSGT8Io0UtLV7SF%2BtAujrp8S3RO7Z9%2BgzbH%2BrS5IvtCSKSHWa0ugw2cC7REaAuWIM%2BlpPEOo%3D&amp;TOPIC_ID=128404" target="_blank">FDA website</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.centerforhealthsecurity.org%2Fcovid-19TestingToolkit%2Fmolecular-based-tests%2Fcurrent-molecular-and-antigen-tests.html&amp;token=8nOAedsnak6NJJsCJ%2F%2FMmZgj7nanXjfF6zyF%2B8VcVsXiaC7ahazWabivBkLGQdPr9XZBZsOnYUhuI42LP3Nrlg0lCj1UE%2BrNKHoY2%2FpUBb%2FB1cNMOh4%2BX7hUK1w0CGvu0y5sOkTt%2F%2FHWXsWcpA%2B0Ow%3D%3D&amp;TOPIC_ID=128404" target="_blank">COVID-19 Testing Toolkit site</a>, which also lists the manufacturer reported sensitivity and specificity [<a href="#rid87">87,88</a>]. Most of these can be performed at the point of care or in a laboratory. Antigen tests that can be performed by the patient at home are also available. </p><p>Impact of the Omicron variant on antigen test accuracy is discussed elsewhere. (See <a class="local">'Impact of SARS-CoV-2 mutations/variants on test accuracy'</a> below.)</p><p class="headingAnchor" id="H987364265"><span class="h1">OTHER DIAGNOSTIC TESTS</span></p><p class="headingAnchor" id="H2813503854"><span class="h2">Serology to identify prior/late infection</span><span class="headingEndMark"> — </span>Serologic tests detect antibodies to SARS-CoV-2 in the blood, and those that have been adequately validated can help identify patients who previously had SARS-CoV-2 infection as well as patients with current infection who have had symptoms for three to four weeks  (<a class="graphic graphic_table graphicRef128419" href="/z/d/graphic/128419.html" rel="external">table 3</a>). Because serologic tests are less likely to be reactive in the first several days to weeks of infection, they have very limited utility for diagnosis in the acute setting [<a href="#rid24">24,89,90</a>]. Checking serology three to four weeks after the onset of symptoms optimizes the accuracy of testing, since test sensitivity beyond five weeks is uncertain [<a href="#rid47">47</a>]. Interpretation of serologic tests in individuals who have received a COVID-19 vaccine is discussed elsewhere. (See <a class="local">'Testing following COVID-19 vaccination'</a> below.)</p><p>We suggest using IgG antibody or total antibody tests rather than IgM antibody, IgA antibody, or IgM/IgG differentiation tests because of their greater accuracy; this is consistent with recommendations from the Infectious Diseases Society of America (IDSA) [<a href="#rid47">47</a>]. If a serologic test to identify prior infection is performed in an individual who has received a spike protein COVID-19 vaccine, a test that detects antibodies to antigens other than the spike protein should be used.</p><p>To maximize the predictive value of the serologic test, assays with high specificity (≥99.5 percent) should be used and testing should be reserved for individuals with a high pretest probability of prior infection; the United States Centers for Disease Control and Prevention (CDC) also <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhcp%2Ftesting%2Fantibody-tests-guidelines.html&amp;token=thbZOJJJ6rJFtpNVY3gorjLjQlHro8eMxIs8sJQk05D%2BYcyFnJS0laYx5GupUZnDYHZYNaikayqcA35J73ounFjts5A%2BKUODY8G9Htx2OHyvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=128404" target="_blank">suggests</a> an alternative strategy of using a two-step testing algorithm, in which an initial positive test is confirmed by a second, different antibody assay [<a href="#rid89">89</a>]. In areas of low seroprevalence or low pretest probability of infection, individual results should be interpreted with caution, since in this setting even serologic tests that have high specificity still have a low positive predictive value (ie, the positive test has a high likelihood of reflecting a false positive) [<a href="#rid91">91,92</a>].</p><p>In the United States, several serologic tests have been granted <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedical-devices%2Femergency-situations-medical-devices%2Femergency-use-authorizations-medical-devices&amp;token=nM7H6bApqRRftmLKRhh9u0U5uGKZ2RuexWl2Xyh5mMwceXImtYk3RzgFab6db%2Ba035MxqYmbgzlLTnC5YfScGSaNP7una6Uw4iZbtmQ5RSU%3D&amp;TOPIC_ID=128404" target="_blank">emergency use authorization (EUA) by the United States Food and Drug Administration (FDA)</a> [<a href="#rid29">29</a>]. These are binding antibody tests that detect SARS-CoV-2 antigens (nucleocapsid or spike protein) and include tests that can be performed at the point of care as well as tests that require specialized equipment and trained laboratory personnel; these also include a test that can be used on home-collected specimens and submitted to a laboratory for results. The FDA has also granted EUA for a test that detects neutralizing antibodies [<a href="#rid93">93</a>]; although such tests are helpful to study the response to infection or vaccination, they do not offer a major diagnostic advantage over binding antibody tests since correlates of protection have not yet been established. The sensitivity and specificity of serologic tests are variable [<a href="#rid94">94</a>]; a catalog of these tests can be found at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcovid19testingtoolkit.centerforhealthsecurity.org%2Ftesting-trackers%2Fserology-tests-for-covid-19&amp;token=lhhoLETR94sKefb4n9qrbvMF98IKwsF7dTZFI5wsjX5lHuoMAZx6LhJxOeK0fisXs8%2BfYQuVw942WB85saW6zI0YsJ%2FtYmhrPd8gyxfrAJavEgrH%2F%2F6WGogzFEUGWy3T&amp;TOPIC_ID=128404" target="_blank">centerforhealthsecurity.org</a>. The FDA is also independently evaluating the accuracy of certain serologic tests for COVID-19 and posting results on its <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fopen.fda.gov%2Fapis%2Fdevice%2Fcovid19serology%2F&amp;token=OrtdQ6xf73gGWXZkCKfvaaSDPJ1JLgQvFEPlMq%2FGaFHmJsmky88i3q1bMlWw%2BrQ0zVaz7Sq1pwR34Jx5%2B3eR%2Fg%3D%3D&amp;TOPIC_ID=128404" target="_blank">website</a>.</p><p>Detectable antibodies generally take several days to weeks to develop, and the time to antibody detection varies by test [<a href="#rid65">65,95-97</a>]. In a systematic review of 38 studies that evaluated the sensitivity of serologic testing by time since symptom onset in patients with COVID-19, IgM was detected in 23 percent by one week, in 58 percent by two weeks, and in 75 percent by three weeks; the corresponding detection rates for IgG were 30, 66, and 88 percent [<a href="#rid98">98</a>]. Other studies have suggested that the rate of positive IgG approaches 100 percent by 16 to 20 days [<a href="#rid46">46,99,100</a>]. </p><p>However, various serologic tests, including in-house laboratory-developed tests, were used in these studies, and their sensitivities within different time frames vary substantially. In particular, some lateral flow assays (which are used for point-of-care tests) are less sensitive than enzyme-linked immunosorbent assays or chemiluminescent immunoassays [<a href="#rid101">101</a>]. </p><p>Specificity also varies by type of serologic assay. In contrast with IgG antibody and total antibody tests, IgM antibody, IgA antibody, and IgM/IgG differentiation tests generally have specificities below 99 percent [<a href="#rid47">47</a>]. Cross-reactivity with other coronaviruses and other viral pathogens is a potential concern [<a href="#rid102">102</a>]. </p><p>Most studies suggest that most individuals have durable, detectable IgG levels up to eight months after infection [<a href="#rid103">103-109</a>]; however, some have reported a faster rate of antibody decline [<a href="#rid110">110-113</a>]. For example, in a study of 1107 individuals with positive SARS-CoV-2 molecular testing in Iceland, total Ig antibody tests were reactive in 90 percent, with titers increasing over the first two months after diagnosis and remaining steady for another two months [<a href="#rid103">103</a>]. In a smaller study, 36 of 40 patients (90 percent) had detectable IgG against spike protein at six to eight months after infection [<a href="#rid107">107</a>]. In contrast, in another study, IgG levels were noted to decline by a median of approximately 75 percent from the acute to early convalescent phase of illness, and at eight weeks following infection, 40 percent of asymptomatic patients and 13 percent of symptomatic patients did not have detectable IgG [<a href="#rid110">110</a>]. The duration that antibodies remain detectable likely depends on the height of the initial antibody response as well as the severity of the infection [<a href="#rid114">114</a>]. </p><p>Large-scale serologic screening with validated tests may be able to provide a better measure of disease activity (by identifying people who were not diagnosed by RT-PCR or who may have had asymptomatic or subclinical infection) and also identify individuals who may have immunity to infection; serologic correlates of protective immunity, however, have not been defined. Until further data are available, the CDC <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhcp%2Ftesting%2Fantibody-tests-guidelines.html&amp;token=thbZOJJJ6rJFtpNVY3gorjLjQlHro8eMxIs8sJQk05D%2BYcyFnJS0laYx5GupUZnDYHZYNaikayqcA35J73ounFjts5A%2BKUODY8G9Htx2OHyvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=128404" target="_blank">recommends</a> that results of antibody testing <strong>not</strong> be used to determine rooming arrangements in congregate settings such as dormitories or prisons, make decisions about return to work, or alter work and personal protective equipment requirements for health care workers and first responders [<a href="#rid89">89</a>]. (See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Viral shedding and period of infectiousness'</a> and  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Immune responses following infection'</a>.)</p><p class="headingAnchor" id="H2815746824"><span class="h2">Tests with limited utility or availability</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breathalyzer</strong> – In the United States, the FDA authorized a breathalyzer that uses gas chromatography-mass spectrometry to detect exhaled volatile organic compounds specific to SARS-CoV-2 infection [<a href="#rid115">115,116</a>]. The contraption is the size of a small suitcase and returns results in approximately three minutes. According to the authorization documents, sensitivity and specificity were 91 and 99.3 percent among a group of asymptomatic and symptomatic individuals compared with PCR on nasopharyngeal swabs. More detailed performance data, as well as other information such as cost, are necessary to inform the optimal role of this device in COVID-19 diagnosis. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral culture</strong> – For safety reasons, specimens from a patient with suspected or documented COVID-19 should <strong>not</strong> be submitted to clinical laboratories for viral culture. Viral culture is mainly reserved for research purposes. (See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Viral shedding and period of infectiousness'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other tests of SARS-CoV-2 immunity</strong> – The clinical utility of tests that can detect cell-mediated immune responses to SARS-CoV-2, such as with an interferon-gamma release assay, is also being explored [<a href="#rid117">117</a>]. </p><p></p><p class="headingAnchor" id="H2709133174"><span class="h1">SPECIAL SITUATIONS</span></p><p class="headingAnchor" id="H2487811045"><span class="h2">Persistent or recurrent positive NAAT during convalescence</span><span class="headingEndMark"> — </span>Patients diagnosed with COVID-19 can have detectable SARS-CoV-2 RNA in upper respiratory tract specimens for weeks after the onset of symptoms [<a href="#rid40">40</a>]. Recurrently positive nucleic acid amplification tests (NAATs) following several negative tests have also been well documented in some patients with COVID-19. </p><p>However, prolonged or recurrent viral RNA detection does not necessarily indicate prolonged infectiousness. Isolation of infectious virus from upper respiratory specimens more than 10 days after illness onset has only rarely been documented in patients who recovered from nonsevere infection [<a href="#rid42">42,118,119</a>]. Additionally, viral RNA levels during convalescence, if detectable, are lower than those detected during acute illness, and studies have suggested that infectious virus cannot be detected below a certain viral threshold [<a href="#rid118">118</a>]. These data and the implications for discontinuing isolation precautions are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Viral shedding and period of infectiousness'</a> and  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Discontinuation of precautions'</a>.)</p><p>In the United States, the Centers for Disease Control and Prevention (CDC) suggests against retesting asymptomatic individuals who were previously diagnosed with SARS-CoV-2 within the prior three months with NAAT because of the low likelihood that a repeat positive NAAT during this interval represents an active infection [<a href="#rid120">120</a>].</p><p class="headingAnchor" id="H3118018327"><span class="h2">Diagnosis of reinfection</span><span class="headingEndMark"> — </span>The diagnosis of reinfection is straightforward (ie, with positive NAAT or antigen testing) when many months have elapsed between the two infections. (See <a class="local">'Diagnosis of SARS-CoV-2 infection'</a> above.) </p><p>However, establishing the diagnosis of reinfection can be challenging when it occurs within a few months of the prior infection. For individuals who warrant testing within three months of an earlier infection, antigen testing is preferred. Because of the possibility of prolonged respiratory shedding of viral RNA following acute infection, a repeat positive NAAT in this setting does not necessarily indicate a new infection. If an NAAT was performed and is positive within three months of an earlier infection, features that increase the likelihood of reinfection include new symptoms consistent with COVID-19, a longer interval since the first infection, and a high viral RNA level on repeat testing (eg, Ct value &lt;33). </p><p>Interpretation of antigen testing in this setting is the same as for the general population. (See <a class="local">'Antigen test interpretation'</a> above.)</p><p class="headingAnchor" id="H2348367199"><span class="h2">Impact of SARS-CoV-2 mutations/variants on test accuracy</span><span class="headingEndMark"> — </span>Over the course of the pandemic, several SARS-CoV-2 variants that have mutations in the spike protein have become prevalent globally. (See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Variants of concern'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact on NAAT</strong> – Some variants have spike mutations (in particular, a deletion at amino acids 69-70) that impact the ability of SARS-CoV-2 NAAT to detect the S gene that encodes the spike protein. Most NAATs will still detect SARS-CoV-2 RNA even if they fail to detect the mutated S gene because they have been designed to detect more than one gene target [<a href="#rid121">121</a>]. S gene target failure can be used as a marker for variants that contain spike protein mutations for surveillance purposes.</p><p></p><p class="bulletIndent1">Most NAATs still detect Omicron and its subvariants; some result in S gene target failure with certain Omicron subvariants. Rare NAATs that are expected to fail to detect specific variants completely are detailed on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedical-devices%2Fcoronavirus-covid-19-and-medical-devices%2Fsars-cov-2-viral-mutations-impact-covid-19-tests%3Futm_medium%3Demail%26utm_source%3Dgovdelivery&amp;token=wMtxOE4QNzTH3A6QY4vPqrb%2Fmq7t1fnrNLrA2xk5NLFw%2FpX3rslFYE5ihoqQZtUdJE1iLgW3fYCOYhj3RsYgVHswqmVVckfzTTpLLVhDWy7t0n2Xx9%2BgCfaFJAJVR8OqyoqQcviq9G5eOzMB1GD%2FOWWh8EHWjQmGo6sEZ%2FWzYcs%3D&amp;TOPIC_ID=128404" target="_blank">US Food and Drug Administration (FDA) website</a> [<a href="#rid122">122,123</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact on antigen tests</strong> – Most antigen tests target nucleocapsid protein, so mutations in the spike protein would not impact the accuracy of such antigen tests.</p><p></p><p class="bulletIndent1">The Omicron variant has four mutations in the nucleocapsid protein, although most antigen tests are still expected to detect Omicron and its subvariants. Although there is some concern that antigen tests may have lower sensitivity for Omicron subvariants compared with other variants, available data do not clearly indicate that antigen tests should be employed differently when Omicron is prevalent. As with other variants, a negative antigen test does not necessarily indicate that a person is not infectious, and when the clinical suspicion for COVID-19 is high, a negative antigen test should be repeated or confirmed with NAAT. (See <a class="local">'Antigen testing'</a> above.) </p><p></p><p class="bulletIndent1">According to the US FDA, certain antigen tests may have lower sensitivity for the Omicron variant, but the data supporting this were not detailed [<a href="#rid122">122</a>]. In contrast, most available evidence suggests that the sensitivity of antigen testing relative to NAAT in detecting the Omicron variant on nasal specimens is similar to that with other SARS-CoV-2 strains (ie, overall sensitivity is modest but sensitivity for high viral levels is high [<a href="#rid124">124-126</a>]). In one study of 731 individuals in California who were tested simultaneously with anterior nasal rapid antigen testing (BinaxNOW) and anterior nasal NAAT during the Omicron surge, of the 296 who tested positive by NAAT, 193 had a positive antigen test (overall sensitivity 65.2 percent) [<a href="#rid127">127</a>]. However, antigen test sensitivity was higher among those whose NAAT indicated higher viral RNA levels (95 percent with Ct &lt;30 and 82 percent with Ct &lt;35). </p><p></p><p class="bulletIndent1">These findings contrast with another unpublished study of 30 vaccinated individuals identified as having early Omicron infection in the setting of near-daily testing. In this study, antigen testing of nasal swabs were almost always negative on the first day or two of diagnosis despite positive simultaneous results from a saliva NAAT, even at high viral RNA levels; the median time to positive antigen test was three days after NAAT positivity [<a href="#rid62">62</a>]. However, it is uncertain whether the discrepancy between antigen testing and NAAT was related to differences in viral levels in saliva versus nasal swab specimens. Among the five individuals who underwent both saliva and nasal NAAT, viral RNA levels appeared to peak in saliva tests one to two days before nasal tests. Performance of antigen testing on saliva or oral specimens has not been validated, and other data suggest that oral specimens do not substantially improve detection of Omicron. In the California study described above, among 49 individuals who had a high viral RNA level (Ct &lt;30) on nasal NAAT and collected both nasal and throat specimens, the antigen test was positive in 86 percent of nasal swabs and 47 percent of throat swabs; either the throat or the nasal swab was positive in 90 percent [<a href="#rid127">127</a>]. </p><p></p><p class="headingAnchor" id="H1762564207"><span class="h2">Testing following COVID-19 vaccination</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral tests</strong> – Virals tests in individuals who have received a COVID-19 vaccine should be interpreted in the same way as in unvaccinated individuals. Vaccination does not influence the results of viral tests, so a positive viral test result in a vaccinated individual should not be attributed to the vaccine. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serology</strong> – COVID-19 vaccination elicits antibodies against the SARS-CoV-2 spike protein. Some serologic tests detect anti-spike antibodies, and these tests cannot distinguish between prior infection and prior vaccination (a reactive result could indicate prior infection, prior vaccination, or both). Some serologic tests only detect antibodies against nucleocapsid protein; vaccines authorized in the United States, Canada, and Europe do not elicit such antibodies, so a reactive result on a nucleocapsid protein-based serologic test in an individual who has received one of these vaccines would suggest a history of infection. However, some evidence suggests that vaccinated individuals are less likely to develop anti-nucleocapsid antibodies after infection than unvaccinated individuals [<a href="#rid128">128</a>]. </p><p></p><p class="headingAnchor" id="H1571919181"><span class="h2">Multisystem inflammatory syndrome in children</span><span class="headingEndMark"> — </span>For children or adolescents with suspected multisystem inflammatory syndrome, testing for SARS-CoV-2 includes both NAAT and serology. Many children with this syndrome have had detectable antibodies to SARS-CoV-2 but a negative NAAT. The diagnosis and evaluation of multisystem inflammatory syndrome are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/128190.html" rel="external">"COVID-19: Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis", section on 'Evaluation'</a>.)</p><p class="headingAnchor" id="H1443029545"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/126613.html" rel="external">"Society guideline links: COVID-19 – Index of guideline topics"</a>.)</p><p class="headingAnchor" id="H2687468119"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/126678.html" rel="external">"Patient education: COVID-19 overview (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/127758.html" rel="external">"Patient education: COVID-19 and pregnancy (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/127544.html" rel="external">"Patient education: COVID-19 and children (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/130329.html" rel="external">"Patient education: COVID-19 vaccines (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2607838323"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical suspicion</strong> – The possibility of COVID-19 should be considered in patients with compatible symptoms  (<a class="graphic graphic_table graphicRef127890" href="/z/d/graphic/127890.html" rel="external">table 1</a>), in particular fever and/or respiratory tract symptoms, who reside in or have traveled to areas with community transmission or who have had potential exposure to SARS-CoV-2 through an outbreak setting or close contact with a confirmed or suspected case. Clinicians should also be aware of the possibility of COVID-19 in patients with severe respiratory illness when no other etiology can be identified. (See <a class="local">'Clinical suspicion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Whom to test</strong> – All symptomatic patients with suspected COVID-19 should undergo testing for SARS-CoV-2. The main indication for testing asymptomatic individuals is recent exposure to SARS-CoV-2; we suggest post-exposure testing be done five to seven days after exposure, although the optimal timing is uncertain. Asymptomatic testing can also be performed for screening in high-risk settings, such as certain congregate settings and hospital settings in high-prevalence regions. (See <a class="local">'Whom to test'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of test </strong>–<strong> </strong>A viral test is necessary to make the diagnosis of SARS-CoV-2 infection: either a nucleic acid amplification test (NAAT, most commonly a reverse-transcription polymerase chain reaction [RT-PCR] assay), or an antigen test. We suggest NAAT, if readily available with a reasonable turnaround time, because of its superior sensitivity; however, antigen tests are more accessible, more convenient, provide results faster than laboratory-based NAAT, and they are good alternatives as long as users appreciate the potential need for repeat testing to optimize sensitivity. (See <a class="local">'Choosing an initial diagnostic test'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>NAAT accuracy and interpretation</strong> – NAATs detect SARS-CoV-2 RNA in patient specimens and are highly specific  (<a class="graphic graphic_table graphicRef128419" href="/z/d/graphic/128419.html" rel="external">table 3</a>); they are most commonly laboratory based, although point-of-care NAATs are also available. They can detect low levels of viral RNA; the precise sensitivity of these tests in the clinical setting likely depends on the type and quality of the specimen obtained, the duration of illness at the time of testing, and the specific assay. (See <a class="local">'NAAT (including RT-PCR)'</a> above.)</p><p></p><p class="bulletIndent2">A positive NAAT for SARS-CoV-2 confirms the diagnosis of COVID-19. (See <a class="local">'Positive NAAT result'</a> above.)</p><p></p><p class="bulletIndent2">For many symptomatic individuals, a single negative NAAT result is sufficient to exclude the diagnosis of COVID-19. However, if initial testing is negative, but the suspicion for COVID-19 remains high, and confirming the presence of infection is important for management or infection control, we suggest repeating the test. In certain situations, NAAT on lower respiratory tract specimens (for hospitalized patients with evidence of lower respiratory tract illness) or serology (for patients with symptoms for at least two weeks) may be a useful adjunctive diagnostic test. (See <a class="local">'Negative initial NAAT result'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antigen test accuracy and interpretation</strong> – Antigen tests can be performed rapidly at home or at the point of care. Positive tests can be interpreted as indicative of SARS-CoV-2 infection. Because they are less sensitive than NAAT, negative antigen tests performed for symptoms or recent exposure should generally be confirmed with repeat testing  (<a class="graphic graphic_algorithm graphicRef134206" href="/z/d/graphic/134206.html" rel="external">algorithm 1</a>). Antigen tests can also be useful for serial screening for infection in high-risk settings (eg, congregate settings). (See <a class="local">'Antigen testing'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limited role for serology</strong> – Tests that detect antibodies to SARS-CoV-2 can help identify patients who previously had COVID-19  (<a class="graphic graphic_table graphicRef128419" href="/z/d/graphic/128419.html" rel="external">table 3</a>). Detectable antibodies generally take several days to weeks to develop; thus, serologic tests have less utility for diagnosis in the acute setting. Serologic tests should be used with caution because of variable performance among available assays, potential for low positive predictive value in settings of low seroprevalence, and uncertain serologic correlates of immunity. (See <a class="local">'Serology to identify prior/late infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpreting tests in vaccinated individuals</strong> – Vaccination status does not influence interpretation of viral test (ie, NAAT or antigen test) results. Most serologic tests target the nucleocapsid protein; only serologic tests that target the spike protein can detect antibody response to currently available vaccines, but they cannot distinguish a vaccine response from prior infection. (See <a class="local">'Testing following COVID-19 vaccination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Detecting infection with Omicron subvariants</strong> – The approach to diagnostic testing in the context of Omicron subvariants is the same as with other variants. Some Omicron subvariants have spike protein mutations that result in S gene target failure in some NAATs. Most NAATs still detect Omicron subvariants since they have more than one gene target. Antigen tests (which generally target the nucleoprotein) are also expected to detect Omicron subvariants. Routine diagnostic testing cannot confirm infection with a specific variant. (See <a class="local">'Impact of SARS-CoV-2 mutations/variants on test accuracy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. Available at: http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed on February 12, 2020).</li><li class="breakAll">Centers for Disease Control and Prevention. 2019 Novel coronavirus, Wuhan, China. Information for Healthcare Professionals. https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html (Accessed on June 19, 2022).</li><li class="breakAll">World Health Organization. Novel Coronavirus (2019-nCoV) technical guidance. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance (Accessed on June 19, 2022).</li><li><a class="nounderline abstract_t">Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19. Cochrane Database Syst Rev 2022; 5:CD013665.</a></li><li><a class="nounderline abstract_t">Cohen PA, Hall LE, John JN, Rapoport AB. The Early Natural History of SARS-CoV-2 Infection: Clinical Observations From an Urban, Ambulatory COVID-19 Clinic. Mayo Clin Proc 2020; 95:1124.</a></li><li><a class="nounderline abstract_t">Tostmann A, Bradley J, Bousema T, et al. Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020. Euro Surveill 2020; 25.</a></li><li><a class="nounderline abstract_t">Makaronidis J, Mok J, Balogun N, et al. Seroprevalence of SARS-CoV-2 antibodies in people with an acute loss in their sense of smell and/or taste in a community-based population in London, UK: An observational cohort study. PLoS Med 2020; 17:e1003358.</a></li><li><a class="nounderline abstract_t">Akinbami LJ, Petersen LR, Sami S, et al. Coronavirus Disease 2019 Symptoms and Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Positivity in a Large Survey of First Responders and Healthcare Personnel, May-July 2020. Clin Infect Dis 2021; 73:e822.</a></li><li><a class="nounderline abstract_t">Dawson P, Rabold EM, Laws RL, et al. Loss of Taste and Smell as Distinguishing Symptoms of Coronavirus Disease 2019. Clin Infect Dis 2021; 72:682.</a></li><li class="breakAll">Infectious Diseases Society of America. COVID-19 Prioritization of Diagnostic Testing. https://www.idsociety.org/globalassets/idsa/public-health/covid-19-prioritization-of-dx-testing.pdf (Accessed on March 22, 2020).</li><li class="breakAll">Centers for Disease Control and Prevention. COVID-19: Quarantine and Isolation. https://www.cdc.gov/coronavirus/2019-ncov/your-health/quarantine-isolation.html (Accessed on January 11, 2022).</li><li class="breakAll">Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19, updated December 23, 2020. https://www.idsociety.org/practice-guideline/covid-19-guideline-diagnostics/ (Accessed on January 14, 2021).</li><li class="breakAll">European Society for Blood and Marrow Transplantation. COVID-19 and BMT. https://www.ebmt.org/covid-19-and-bmt (Accessed on June 10, 2020).</li><li class="breakAll">Centers for Disease Control and Prevention. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons Under Investigation (PUIs) for Coronavirus Disease 2019 (COVID-19). https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html (Accessed on October 15, 2020).</li><li><a class="nounderline abstract_t">Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis. Gastroenterology 2020; 159:81.</a></li><li><a class="nounderline abstract_t">Azzolini C, Donati S, Premi E, et al. SARS-CoV-2 on Ocular Surfaces in a Cohort of Patients With COVID-19 From the Lombardy Region, Italy. JAMA Ophthalmol 2021; 139:956.</a></li><li><a class="nounderline abstract_t">Chen W, Lan Y, Yuan X, et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerg Microbes Infect 2020; 9:469.</a></li><li><a class="nounderline abstract_t">Wu X, Cai Y, Huang X, et al. Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China. Emerg Infect Dis 2020; 26:1324.</a></li><li><a class="nounderline abstract_t">Ding Q, Lu P, Fan Y, et al. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol 2020; 92:1549.</a></li><li><a class="nounderline abstract_t">Kim D, Quinn J, Pinsky B, et al. Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens. JAMA 2020; 323:2085.</a></li><li><a class="nounderline abstract_t">Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020; 323:2052.</a></li><li><a class="nounderline abstract_t">Zha L, Shen J, Tefsen B, et al. Clinical features and outcomes of adult COVID-19 patients co-infected with Mycoplasma pneumoniae. J Infect 2020; 81:e12.</a></li><li><a class="nounderline abstract_t">Patel A, Jernigan DB, 2019-nCoV CDC Response Team. Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:140.</a></li><li><a class="nounderline abstract_t">Fang FC, Naccache SN, Greninger AL. The Laboratory Diagnosis of Coronavirus Disease 2019- Frequently Asked Questions. Clin Infect Dis 2020; 71:2996.</a></li><li class="breakAll">World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117 (Accessed on April 22, 2020).</li><li><a class="nounderline abstract_t">Joung J, Ladha A, Saito M, et al. Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing. N Engl J Med 2020; 383:1492.</a></li><li><a class="nounderline abstract_t">Brandsma E, Verhagen HJMP, van de Laar TJW, et al. Rapid, sensitive and specific SARS coronavirus-2 detection: a multi-center comparison between standard qRT-PCR and CRISPR based DETECTR. J Infect Dis 2020.</a></li><li><a class="nounderline abstract_t">Rauch JN, Valois E, Ponce-Rojas JC, et al. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Screening Using Reverse Transcriptase-Quantitative Polymerase Chain Reaction or CRISPR-Based Assays in Asymptomatic College Students. JAMA Netw Open 2021; 4:e2037129.</a></li><li class="breakAll">US Food and Drug Administration. Emergency Use Authorizations. https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations (Accessed on April 16, 2020).</li><li class="breakAll">US Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-test-patient-home-sample-collection (Accessed on April 22, 2020).</li><li class="breakAll">US Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-standalone-home-sample-collection-kit-can-be-used (Accessed on May 18, 2020).</li><li class="breakAll">Food and Drug Administration. Letter for EUA of Lucira COVID-19 All-In-One Test Kit. https://www.fda.gov/media/143810/download (Accessed on November 20, 2020).</li><li class="breakAll">US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Informs Public About Possible Accuracy Concerns with Abbott ID NOW Point-of-Care Test https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-informs-public-about-possible-accuracy-concerns-abbott-id-now-point (Accessed on May 19, 2020).</li><li><a class="nounderline abstract_t">Gibani MM, Toumazou C, Sohbati M, et al. Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study. Lancet Microbe 2020; 1:e300.</a></li><li><a class="nounderline abstract_t">Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev 2021; 3:CD013705.</a></li><li><a class="nounderline abstract_t">Hogan CA, Sahoo MK, Pinsky BA. Sample Pooling as a Strategy to Detect Community Transmission of SARS-CoV-2. JAMA 2020; 323:1967.</a></li><li><a class="nounderline abstract_t">Yelin I, Aharony N, Tamar ES, et al. Evaluation of COVID-19 RT-qPCR Test in Multi sample Pools. Clin Infect Dis 2020; 71:2073.</a></li><li><a class="nounderline abstract_t">Abdalhamid B, Bilder CR, McCutchen EL, et al. Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources. Am J Clin Pathol 2020; 153:715.</a></li><li><a class="nounderline abstract_t">Pilcher CD, Westreich D, Hudgens MG. Group Testing for Severe Acute Respiratory Syndrome- Coronavirus 2 to Enable Rapid Scale-up of Testing and Real-Time Surveillance of Incidence. J Infect Dis 2020; 222:903.</a></li><li><a class="nounderline abstract_t">He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020; 26:672.</a></li><li><a class="nounderline abstract_t">Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020; 581:465.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Symptom-Based Strategy to Discontinue Isolation for Persons with COVID-19: Decision Memo. https://www.cdc.gov/coronavirus/2019-ncov/community/strategy-discontinue-isolation.html (Accessed on May 04, 2020).</li><li><a class="nounderline abstract_t">Mack CD, DiFiori J, Tai CG, et al. SARS-CoV-2 Transmission Risk Among National Basketball Association Players, Staff, and Vendors Exposed to Individuals With Positive Test Results After COVID-19 Recovery During the 2020 Regular and Postseason. JAMA Intern Med 2021; 181:960.</a></li><li class="breakAll">World Health Organization. Coronavirus disease (COVID-19) technical guidance: Surveillance and case definitions. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/surveillance-and-case-definitions (Accessed on February 28, 2020).</li><li class="breakAll">World Health Organization. Diagnostic testing for SARS-CoV-2. Interim guidance. https://www.who.int/publications/i/item/diagnostic-testing-for-sars-cov-2 (Accessed on September 21, 2020).</li><li><a class="nounderline abstract_t">Caturegli G, Materi J, Howard BM, Caturegli P. Clinical Validity of Serum Antibodies to SARS-CoV-2 : A Case-Control Study. Ann Intern Med 2020; 173:614.</a></li><li class="breakAll">Hansen KE, Caliendo AM, Arias CA, et al. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing. Auguest 18, 2020 https://www.idsociety.org/practice-guideline/covid-19-guideline-serology/ (Accessed on August 19, 2020).</li><li><a class="nounderline abstract_t">Nalla AK, Casto AM, Huang MW, et al. Comparative Performance of SARS-CoV-2 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit. J Clin Microbiol 2020; 58.</a></li><li><a class="nounderline abstract_t">Lieberman JA, Pepper G, Naccache SN, et al. Comparison of Commercially Available and Laboratory-Developed Assays for In Vitro Detection of SARS-CoV-2 in Clinical Laboratories. J Clin Microbiol 2020; 58.</a></li><li class="breakAll">False Positive Results with BD SARS-CoV-2 Reagents for the BD Max System - Letter to Clinical Laboratory Staff and Health Care Providers. https://www.fda.gov/medical-devices/letters-health-care-providers/false-positive-results-bd-sars-cov-2-reagents-bd-max-system-letter-clinical-laboratory-staff-and (Accessed on July 10, 2020).</li><li><a class="nounderline abstract_t">Weissleder R, Lee H, Ko J, Pittet MJ. COVID-19 diagnostics in context. Sci Transl Med 2020; 12.</a></li><li><a class="nounderline abstract_t">Long DR, Gombar S, Hogan CA, et al. Occurrence and Timing of Subsequent SARS-CoV-2 RT-PCR Positivity Among Initially Negative Patients. Clin Infect Dis 2020.</a></li><li><a class="nounderline abstract_t">Fang Y, Zhang H, Xie J, et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. Radiology 2020; 296:E115.</a></li><li><a class="nounderline abstract_t">Lee TH, Junhao Lin R, Lin RTP, et al. Testing for SARS-CoV-2: Can We Stop at 2? Clin Infect Dis 2020; 71:2246.</a></li><li><a class="nounderline abstract_t">Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA 2020; 323:1843.</a></li><li><a class="nounderline abstract_t">COVID-19 Investigation Team. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Nat Med 2020; 26:861.</a></li><li><a class="nounderline abstract_t">Butler-Laporte G, Lawandi A, Schiller I, et al. Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection of SARS-CoV-2: A Systematic Review and Meta-analysis. JAMA Intern Med 2021; 181:353.</a></li><li><a class="nounderline abstract_t">Tsang NNY, So HC, Ng KY, et al. Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis. Lancet Infect Dis 2021; 21:1233.</a></li><li><a class="nounderline abstract_t">Tu YP, Jennings R, Hart B, et al. Swabs Collected by Patients or Health Care Workers for SARS-CoV-2 Testing. N Engl J Med 2020; 383:494.</a></li><li><a class="nounderline abstract_t">McCulloch DJ, Kim AE, Wilcox NC, et al. Comparison of Unsupervised Home Self-collected Midnasal Swabs With Clinician-Collected Nasopharyngeal Swabs for Detection of SARS-CoV-2 Infection. JAMA Netw Open 2020; 3:e2016382.</a></li><li><a class="nounderline abstract_t">Yu F, Yan L, Wang N, et al. Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. Clin Infect Dis 2020; 71:793.</a></li><li class="breakAll">Adamson B, Sikka R, Wyllie AL, Premsrirut P. Discordant SARS-CoV-2 PCR and Rapid Antigen Test Results When Infectious: A December 2021 Occupational Case Series. UNPUBLISHED. https://www.medrxiv.org/content/10.1101/2022.01.04.22268770v1 (Accessed on January 11, 2022).</li><li><a class="nounderline abstract_t">Marais G, Hsiao NY, Iranzadeh A, et al. Improved oral detection is a characteristic of Omicron infection and has implications for clinical sampling and tissue tropism. J Clin Virol 2022; 152:105170.</a></li><li><a class="nounderline abstract_t">Kucirka LM, Lauer SA, Laeyendecker O, et al. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure. Ann Intern Med 2020; 173:262.</a></li><li><a class="nounderline abstract_t">Guo L, Ren L, Yang S, et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis 2020; 71:778.</a></li><li><a class="nounderline abstract_t">Furukawa NW, Brooks JT, Sobel J. Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic. Emerg Infect Dis 2020; 26.</a></li><li><a class="nounderline abstract_t">Mack CD, Osterholm M, Wasserman EB, et al. Optimizing SARS-CoV-2 Surveillance in the United States: Insights From the National Football League Occupational Health Program. Ann Intern Med 2021; 174:1081.</a></li><li><a class="nounderline abstract_t">McDonald S, Courtney DM, Clark AE, et al. Diagnostic Performance of a Rapid Point-of-care Test for SARS-CoV-2 in an Urban Emergency Department Setting. Acad Emerg Med 2020; 27:764.</a></li><li class="breakAll">IDSA and AMP joint statement on the use of SARS-CoV-2 PCR cycle threshold (Ct) values for clinical decision-making. https://www.idsociety.org/globalassets/idsa/public-health/covid-19/idsa-amp-statement.pdf (Accessed on April 12, 2021).</li><li><a class="nounderline abstract_t">Pray IW, Ford L, Cole D, et al. Performance of an Antigen-Based Test for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses - Wisconsin, September-October 2020. MMWR Morb Mortal Wkly Rep 2021; 69:1642.</a></li><li><a class="nounderline abstract_t">Prince-Guerra JL, Almendares O, Nolen LD, et al. Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites - Pima County, Arizona, November 3-17, 2020. MMWR Morb Mortal Wkly Rep 2021; 70:100.</a></li><li class="breakAll">World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays. Interim guidance. https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays (Accessed on September 21, 2020).</li><li class="breakAll">Infectious Diseases Society of America. IDSA Guidelines on the Diagnosis of COVID-19: Antigen Testing. https://www.idsociety.org/practice-guideline/covid-19-guideline-antigen-testing/ (Accessed on June 14, 2022).</li><li class="breakAll">At-Home COVID-19 Antigen Tests-Take Steps to Reduce Your Risk of False Negative: FDA Safety Communication https://www.fda.gov/medical-devices/safety-communications/home-covid-19-antigen-tests-take-steps-reduce-your-risk-false-negative-fda-safety-communication (Accessed on August 18, 2022).</li><li><a class="nounderline abstract_t">Soni A, Herbert C, Lin H, et al. Performance of Rapid Antigen Tests to Detect Symptomatic and Asymptomatic SARS-CoV-2 Infection. medRxiv 2023.</a></li><li><a class="nounderline abstract_t">Paltiel AD, Zheng A, Walensky RP. Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States. JAMA Netw Open 2020; 3:e2016818.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Interim guidance for antigen testing for SARS-CoV-2. https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html (Accessed on June 14, 2021).</li><li><a class="nounderline abstract_t">Revollo B, Blanco I, Soler P, et al. Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial. Lancet Infect Dis 2021; 21:1365.</a></li><li><a class="nounderline abstract_t">Brandal LT, MacDonald E, Veneti L, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Euro Surveill 2021; 26.</a></li><li><a class="nounderline abstract_t">Moreno GK, Braun KM, Pray IW, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in Intercollegiate Athletics Not Fully Mitigated With Daily Antigen Testing. Clin Infect Dis 2021; 73:S45.</a></li><li><a class="nounderline abstract_t">Brümmer LE, Katzenschlager S, Gaeddert M, et al. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis. PLoS Med 2021; 18:e1003735.</a></li><li><a class="nounderline abstract_t">Dinnes J, Sharma P, Berhane S, et al. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev 2022; 7:CD013705.</a></li><li><a class="nounderline abstract_t">Chu VT, Schwartz NG, Donnelly MAP, et al. Comparison of Home Antigen Testing With RT-PCR and Viral Culture During the Course of SARS-CoV-2 Infection. JAMA Intern Med 2022; 182:701.</a></li><li><a class="nounderline abstract_t">Pekosz A, Parvu V, Li M, et al. Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture. Clin Infect Dis 2021; 73:e2861.</a></li><li><a class="nounderline abstract_t">McKay SL, Tobolowsky FA, Moritz ED, et al. Performance Evaluation of Serial SARS-CoV-2 Rapid Antigen Testing During a Nursing Home Outbreak. Ann Intern Med 2021; 174:945.</a></li><li><a class="nounderline abstract_t">Ke R, Martinez PP, Smith RL, et al. Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. Nat Microbiol 2022; 7:640.</a></li><li class="breakAll">https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas#individual-antigen (Accessed on December 11, 2020).</li><li class="breakAll">COVID-19 Testing Toolkit. Antigen and Molecular Tests for COVID-19. https://www.centerforhealthsecurity.org/covid-19TestingToolkit/molecular-based-tests/current-molecular-and-antigen-tests.html (Accessed on October 23, 2021).</li><li class="breakAll">Centers for Disease Control and Prevention. Interim Guidelines for COVID-19 Antibody Testing in Clinical and Public Health Settings https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html?deliveryName=USCDC_2067-DM29085 (Accessed on May 26, 2020).</li><li><a class="nounderline abstract_t">Cheng MP, Yansouni CP, Basta NE, et al. Serodiagnostics for Severe Acute Respiratory Syndrome-Related Coronavirus 2 : A Narrative Review. Ann Intern Med 2020; 173:450.</a></li><li><a class="nounderline abstract_t">Bryant JE, Azman AS, Ferrari MJ, et al. Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward. Sci Immunol 2020; 5.</a></li><li><a class="nounderline abstract_t">Mulchandani R, Jones HE, Taylor-Phillips S, et al. Accuracy of UK Rapid Test Consortium (UK-RTC) "AbC-19 Rapid Test" for detection of previous SARS-CoV-2 infection in key workers: test accuracy study. BMJ 2020; 371:m4262.</a></li><li class="breakAll">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-test-detects-neutralizing-antibodies-recent-or (Accessed on November 20, 2020).</li><li><a class="nounderline abstract_t">National SARS-CoV-2 Serology Assay Evaluation Group. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis 2020; 20:1390.</a></li><li><a class="nounderline abstract_t">Zhao J, Yuan Q, Wang H, et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis 2020; 71:2027.</a></li><li><a class="nounderline abstract_t">Qu J, Wu C, Li X, et al. Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71:2255.</a></li><li><a class="nounderline abstract_t">Zhang G, Nie S, Zhang Z, Zhang Z. Longitudinal Change of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Patients with Coronavirus Disease 2019. J Infect Dis 2020; 222:183.</a></li><li><a class="nounderline abstract_t">Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev 2020; 6:CD013652.</a></li><li><a class="nounderline abstract_t">Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020; 26:845.</a></li><li><a class="nounderline abstract_t">Wang X, Guo X, Xin Q, et al. Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients. Clin Infect Dis 2020; 71:2688.</a></li><li><a class="nounderline abstract_t">Lisboa Bastos M, Tavaziva G, Abidi SK, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ 2020; 370:m2516.</a></li><li><a class="nounderline abstract_t">Lustig Y, Keler S, Kolodny R, et al. Potential Antigenic Cross-reactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Dengue Viruses. Clin Infect Dis 2021; 73:e2444.</a></li><li><a class="nounderline abstract_t">Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med 2020; 383:1724.</a></li><li><a class="nounderline abstract_t">Isho B, Abe KT, Zuo M, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol 2020; 5.</a></li><li><a class="nounderline abstract_t">Iyer AS, Jones FK, Nodoushani A, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol 2020; 5.</a></li><li><a class="nounderline abstract_t">Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 2020; 370:1227.</a></li><li><a class="nounderline abstract_t">Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021; 371.</a></li><li><a class="nounderline abstract_t">Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N Engl J Med 2021; 384:533.</a></li><li><a class="nounderline abstract_t">Arkhipova-Jenkins I, Helfand M, Armstrong C, et al. Antibody Response After SARS-CoV-2 Infection and Implications for Immunity : A Rapid Living Review. Ann Intern Med 2021; 174:811.</a></li><li><a class="nounderline abstract_t">Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020; 26:1200.</a></li><li><a class="nounderline abstract_t">Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med 2020; 383:1085.</a></li><li><a class="nounderline abstract_t">Patel MM, Thornburg NJ, Stubblefield WB, et al. Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee. JAMA 2020; 324:1781.</a></li><li><a class="nounderline abstract_t">Perreault J, Tremblay T, Fournier MJ, et al. Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset. Blood 2020; 136:2588.</a></li><li><a class="nounderline abstract_t">Self WH, Tenforde MW, Stubblefield WB, et al. Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network - 12 States, April-August 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1762.</a></li><li class="breakAll">US FDA. Coronavirus (COVID-19) Update: FDA Authorizes First COVID-19 Diagnostic Test Using Breath Samples https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-covid-19-diagnostic-test-using-breath-samples (Accessed on April 21, 2022).</li><li class="breakAll">Food and Drug Administration. Letter for EUA of The InspectIR COVID-19 Breathalyzer. https://www.fda.gov/media/157723/download (Accessed on April 25, 2022).</li><li><a class="nounderline abstract_t">Murugesan K, Jagannathan P, Pham TD, et al. Interferon-γ Release Assay for Accurate Detection of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Response. Clin Infect Dis 2021; 73:e3130.</a></li><li><a class="nounderline abstract_t">Bullard J, Dust K, Funk D, et al. Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples. Clin Infect Dis 2020; 71:2663.</a></li><li><a class="nounderline abstract_t">Liu WD, Chang SY, Wang JT, et al. Prolonged virus shedding even after seroconversion in a patient with COVID-19. J Infect 2020; 81:318.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Clinical Questions about COVID-19: Questions and Answers. https://www.cdc.gov/coronavirus/2019-ncov/hcp/faq.html (Accessed on August 14, 2020).</li><li class="breakAll">US Food and Drug Administration. Genetic Variants of SARS-CoV-2 May Lead to False Negative Results with Molecular Tests for Detection of SARS-CoV-2 - Letter to Clinical Laboratory Staff and Health Care Providers. https://www.fda.gov/medical-devices/letters-health-care-providers/genetic-variants-sars-cov-2-may-lead-false-negative-results-molecular-tests-detection-sars-cov-2 (Accessed on January 14, 2021).</li><li class="breakAll">US Food and Drug Administration. SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests: Omicron Variant: Impact on Molecular Tests (As of 12/22/2021). https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests#omicronvariantimpact (Accessed on January 11, 2022).</li><li class="breakAll">US Food and Drug Administration. SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests. https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests?utm_medium=email&amp;utm_source=govdelivery (Accessed on December 24, 2021).</li><li><a class="nounderline abstract_t">Regan J, Flynn JP, Choudhary MC, et al. Detection of the Omicron Variant Virus With the Abbott BinaxNow SARS-CoV-2 Rapid Antigen Assay. Open Forum Infect Dis 2022; 9:ofac022.</a></li><li class="breakAll">Kanjilal S, Chalise S, Shah A, et al. Analytic sensitivity of the Abbott BinaxNOW lateral flow immunochromatographic assay for the SARS-CoV-2 Omicron variant. UNPUBLISHED. https://www.medrxiv.org/content/10.1101/2022.01.10.22269033v1 (Accessed on February 24, 2022).</li><li><a class="nounderline abstract_t">Drain PK, Bemer M, Morton JF, et al. Accuracy of 2 Rapid Antigen Tests During 3 Phases of SARS-CoV-2 Variants. JAMA Netw Open 2022; 5:e2228143.</a></li><li><a class="nounderline abstract_t">Schrom J, Marquez C, Pilarowski G, et al. Comparison of SARS-CoV-2 Reverse Transcriptase Polymerase Chain Reaction and BinaxNOW Rapid Antigen Tests at a Community Site During an Omicron Surge : A Cross-Sectional Study. Ann Intern Med 2022; 175:682.</a></li><li><a class="nounderline abstract_t">Follmann D, Janes HE, Buhule OD, et al. Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. Ann Intern Med 2022; 175:1258.</a></li></ol></div><div id="topicVersionRevision">Topic 128404 Version 56.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. Available at: http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed on February 12, 2020).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Centers for Disease Control and Prevention. 2019 Novel coronavirus, Wuhan, China. Information for Healthcare Professionals. https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html (Accessed on June 19, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : World Health Organization. Novel Coronavirus (2019-nCoV) technical guidance. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance (Accessed on June 19, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35593186" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32451119" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The Early Natural History of SARS-CoV-2 Infection: Clinical Observations From an Urban, Ambulatory COVID-19 Clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32347200" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33001967" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Seroprevalence of SARS-CoV-2 antibodies in people with an acute loss in their sense of smell and/or taste in a community-based population in London, UK: An observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33515250" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Coronavirus Disease 2019 Symptoms and Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Positivity in a Large Survey of First Responders and Healthcare Personnel, May-July 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32562541" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Loss of Taste and Smell as Distinguishing Symptoms of Coronavirus Disease 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32562541" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Loss of Taste and Smell as Distinguishing Symptoms of Coronavirus Disease 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32562541" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Loss of Taste and Smell as Distinguishing Symptoms of Coronavirus Disease 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32562541" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Loss of Taste and Smell as Distinguishing Symptoms of Coronavirus Disease 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32562541" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Loss of Taste and Smell as Distinguishing Symptoms of Coronavirus Disease 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32562541" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Loss of Taste and Smell as Distinguishing Symptoms of Coronavirus Disease 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32251668" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33662099" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : SARS-CoV-2 on Ocular Surfaces in a Cohort of Patients With COVID-19 From the Lombardy Region, Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32102625" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32160148" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32196707" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32293646" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32320003" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32652163" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical features and outcomes of adult COVID-19 patients co-infected with Mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32027631" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32511679" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The Laboratory Diagnosis of Coronavirus Disease 2019- Frequently Asked Questions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32511679" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The Laboratory Diagnosis of Coronavirus Disease 2019- Frequently Asked Questions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32937062" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33038252" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Rapid, sensitive and specific SARS coronavirus-2 detection: a multi-center comparison between standard qRT-PCR and CRISPR based DETECTR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33570576" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Screening Using Reverse Transcriptase-Quantitative Polymerase Chain Reaction or CRISPR-Based Assays in Asymptomatic College Students.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33570576" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Screening Using Reverse Transcriptase-Quantitative Polymerase Chain Reaction or CRISPR-Based Assays in Asymptomatic College Students.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33570576" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Screening Using Reverse Transcriptase-Quantitative Polymerase Chain Reaction or CRISPR-Based Assays in Asymptomatic College Students.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33570576" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Screening Using Reverse Transcriptase-Quantitative Polymerase Chain Reaction or CRISPR-Based Assays in Asymptomatic College Students.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33570576" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Screening Using Reverse Transcriptase-Quantitative Polymerase Chain Reaction or CRISPR-Based Assays in Asymptomatic College Students.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33570576" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Screening Using Reverse Transcriptase-Quantitative Polymerase Chain Reaction or CRISPR-Based Assays in Asymptomatic College Students.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32964211" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33760236" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32250394" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Sample Pooling as a Strategy to Detect Community Transmission of SARS-CoV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32358960" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Evaluation of COVID-19 RT-qPCR Test in Multi sample Pools.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32304208" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32592581" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Group Testing for Severe Acute Respiratory Syndrome- Coronavirus 2 to Enable Rapid Scale-up of Testing and Real-Time Surveillance of Incidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32296168" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Temporal dynamics in viral shedding and transmissibility of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32235945" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Virological assessment of hospitalized patients with COVID-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32235945" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Virological assessment of hospitalized patients with COVID-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33885715" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : SARS-CoV-2 Transmission Risk Among National Basketball Association Players, Staff, and Vendors Exposed to Individuals With Positive Test Results After COVID-19 Recovery During the 2020 Regular and Postseason.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33885715" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : SARS-CoV-2 Transmission Risk Among National Basketball Association Players, Staff, and Vendors Exposed to Individuals With Positive Test Results After COVID-19 Recovery During the 2020 Regular and Postseason.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33885715" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : SARS-CoV-2 Transmission Risk Among National Basketball Association Players, Staff, and Vendors Exposed to Individuals With Positive Test Results After COVID-19 Recovery During the 2020 Regular and Postseason.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32628534" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical Validity of Serum Antibodies to SARS-CoV-2 : A Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32628534" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical Validity of Serum Antibodies to SARS-CoV-2 : A Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32269100" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Comparative Performance of SARS-CoV-2 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32350048" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Comparison of Commercially Available and Laboratory-Developed Assays for In Vitro Detection of SARS-CoV-2 in Clinical Laboratories.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32350048" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Comparison of Commercially Available and Laboratory-Developed Assays for In Vitro Detection of SARS-CoV-2 in Clinical Laboratories.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32493791" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : COVID-19 diagnostics in context.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32506118" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Occurrence and Timing of Subsequent SARS-CoV-2 RT-PCR Positivity Among Initially Negative Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32073353" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32306042" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Testing for SARS-CoV-2: Can We Stop at 2?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32159775" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Detection of SARS-CoV-2 in Different Types of Clinical Specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32327757" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33449069" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection of SARS-CoV-2: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33857405" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32492294" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Swabs Collected by Patients or Health Care Workers for SARS-CoV-2 Testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32697321" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Comparison of Unsupervised Home Self-collected Midnasal Swabs With Clinician-Collected Nasopharyngeal Swabs for Detection of SARS-CoV-2 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32221523" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32221523" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35525108" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Improved oral detection is a characteristic of Omicron infection and has implications for clinical sampling and tissue tropism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32422057" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32198501" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32364890" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34125571" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Optimizing SARS-CoV-2 Surveillance in the United States: Insights From the National Football League Occupational Health Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32492760" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Diagnostic Performance of a Rapid Point-of-care Test for SARS-CoV-2 in an Urban Emergency Department Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32492760" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Diagnostic Performance of a Rapid Point-of-care Test for SARS-CoV-2 in an Urban Emergency Department Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33382679" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Performance of an Antigen-Based Test for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses - Wisconsin, September-October 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33476316" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites - Pima County, Arizona, November 3-17, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33476316" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites - Pima County, Arizona, November 3-17, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33476316" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites - Pima County, Arizona, November 3-17, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33476316" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites - Pima County, Arizona, November 3-17, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35982680" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Performance of Rapid Antigen Tests to Detect Symptomatic and Asymptomatic SARS-CoV-2 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32735339" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32735339" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34051886" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34915975" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33977295" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in Intercollegiate Athletics Not Fully Mitigated With Daily Antigen Testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34383750" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35866452" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35486394" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Comparison of Home Antigen Testing With RT-PCR and Viral Culture During the Course of SARS-CoV-2 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33479756" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33900791" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Performance Evaluation of Serial SARS-CoV-2 Rapid Antigen Testing During a Nursing Home Outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35484231" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35484231" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35484231" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35484231" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32496919" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Serodiagnostics for Severe Acute Respiratory Syndrome-Related Coronavirus 2 : A Narrative Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32430309" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33177070" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Accuracy of UK Rapid Test Consortium (UK-RTC) "AbC-19 Rapid Test" for detection of previous SARS-CoV-2 infection in key workers: test accuracy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33177070" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Accuracy of UK Rapid Test Consortium (UK-RTC) "AbC-19 Rapid Test" for detection of previous SARS-CoV-2 infection in key workers: test accuracy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32979318" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32221519" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32337590" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32358956" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Longitudinal Change of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Patients with Coronavirus Disease 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32584464" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Antibody tests for identification of current and past infection with SARS-CoV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32350462" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Antibody responses to SARS-CoV-2 in patients with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32497196" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32611558" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32797228" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Potential Antigenic Cross-reactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Dengue Viruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32871063" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Humoral Immune Response to SARS-CoV-2 in Iceland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33033173" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33033172" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33115920" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33408181" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33369366" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33721517" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Antibody Response After SARS-CoV-2 Infection and Implications for Immunity : A Rapid Living Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32555424" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32706954" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32940635" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33001206" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33237893" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network - 12 States, April-August 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33237893" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network - 12 States, April-August 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33237893" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network - 12 States, April-August 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33035306" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Interferon-γRelease Assay for Accurate Detection of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32442256" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32283147" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Prolonged virus shedding even after seroconversion in a patient with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32283147" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Prolonged virus shedding even after seroconversion in a patient with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32283147" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Prolonged virus shedding even after seroconversion in a patient with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32283147" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Prolonged virus shedding even after seroconversion in a patient with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32283147" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Prolonged virus shedding even after seroconversion in a patient with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35169591" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Detection of the Omicron Variant Virus With the Abbott BinaxNow SARS-CoV-2 Rapid Antigen Assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35169591" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Detection of the Omicron Variant Virus With the Abbott BinaxNow SARS-CoV-2 Rapid Antigen Assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36001317" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Accuracy of 2 Rapid Antigen Tests During 3 Phases of SARS-CoV-2 Variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35286144" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Comparison of SARS-CoV-2 Reverse Transcriptase Polymerase Chain Reaction and BinaxNOW Rapid Antigen Tests at a Community Site During an Omicron Surge : A Cross-Sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35785530" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
